TRANSAMINASEN

European patent · EP3307881 · In force

Register entry

Publication number
EP3307881
Application number
EP16734565
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 10, 2016
Published
Apr 18, 2018
Granted
Feb 24, 2021
Protection ends at the latest
Jun 9, 2036
Next annual fee due
Jun 30, 2027
IPC classes
C12N 9/10 (2006.01)
Priority
EP 15171924 12.06.2015
PCT application
PCT/EP2016/063393 10.06.2016
PCT publication
WO2016/198665 15.12.2016
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Jun 30, 2022

    Change

    Published in Swissreg on 30.06.2022

  6. Jan 5, 2022

    Change

    Published in Swissreg on 05.01.2022

  7. Feb 24, 2021

    Granted

    Published in Swissreg on 24.02.2021

Parties

Holder

c-LEcta GmbH

Perlickstrasse 5, 04103 Leipzig, DE

Inventor

VOGEL, Andreas

04105 Leipzig, DE

BAYER, Sally

04207 Leipzig, DE

CZAJA, Rico

04155 Leipzig, DE

BARTSCH, Sebastian

04317 Leipzig, DE

SCHWARZE, Daniel

07749 Jena, DE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.